{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:44:54Z","timestamp":1787939094854,"version":"build-2784847793"},"reference-count":21,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2025,8,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Clinical and Laboratory Standards Institute (CLSI) M100Ed24 (2024) states that\n                      <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic>\n                      susceptible to oral penicillin can be considered susceptible to various \u03b2-lactams, including oral cephalosporins. However, surrogacy guidance is not available for isolates nonsusceptible to oral penicillin. Instead, such isolates require specific MIC testing and interpretations for reporting susceptibility to oral cephalosporins, for which susceptibility testing is limited in most automated systems, and consequently restricts information pertaining to oral cephalosporins at an individual institution. This study evaluated the ability of the penicillin breakpoints to predict cefpodoxime and ceftriaxone susceptibilities against a recent collection of\n                      <jats:italic toggle=\"yes\">S. pneumoniae<\/jats:italic>\n                      from United States hospitals according to CLSI guidelines. The susceptible breakpoint for oral penicillin (\u22640.06 mg\/L) predicted susceptibility to cefpodoxime and ceftriaxone. However, when isolates were nonsusceptible to oral penicillin (MIC, &gt;0.06 mg\/L), susceptibility to cefpodoxime could not be predicted due to a low categorical agreement (CA) (78.4%). Parenteral penicillin breakpoints also could not predict cefpodoxime susceptibility due to the elevated number of very major errors and a CA of 76.8%; however, these breakpoints could still be used as a surrogate marker to predict ceftriaxone susceptibility. Finally, ceftriaxone could be used for surrogate testing of cefpodoxime by applying breakpoints (\u22640.25 mg\/L for susceptible; 0.5 mg\/L for intermediate; \u22651 mg\/L for resistant) lower than the current clinical cutoffs. These analyses showed that isolates nonsusceptible to oral penicillin cannot be considered susceptible to cefpodoxime, and caution should be used when prescribing oral cephalosporins for the empiric treatment of community-acquired bacterial pneumonia.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        Susceptibility results to oral cephalosporins are rarely available to guide therapy due to the limited number of drugs evaluated on common automated antimicrobial susceptibility testing (AST) systems (i.e., Vitek 2, MicroScan, and Phoenix). In addition, disk diffusion methods for determining\n                        <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic>\n                        susceptibility to \u03b2-lactam agents are not reliable, and a quantitative method, such as broth microdilution or gradient strips, is required. In addition, the epidemiology and serotypes of\n                        <jats:italic toggle=\"yes\">S. pneumoniae<\/jats:italic>\n                        are constantly evolving; therefore, this work provides a re-evaluation of surrogacy testing for \u03b2-lactam agents against\n                        <jats:italic toggle=\"yes\">S. pneumoniae<\/jats:italic>\n                        recently recovered from United States laboratories. The data provide the possible use of ceftriaxone MIC for determining cefpodoxime susceptibility. This should be of interest to microbiology laboratories and the scientific community.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/jcm.00027-25","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T09:00:11Z","timestamp":1750755611000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":2,"title":["Re-evaluation of penicillin and ceftriaxone MIC results to predict susceptibility to the oral cephalosporin, cefpodoxime, in\n                    <i>Streptococcus pneumoniae<\/i>\n                    clinical isolates from the United States according to CLSI guidelines (2019\u20132021)"],"prefix":"10.1128","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":true,"given":"Rodrigo E.","family":"Mendes","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qv6pw23","id-type":"ROR","asserted-by":"publisher"}],"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica V.","family":"Pierce","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019g7bh20","id-type":"ROR","asserted-by":"publisher"}],"name":"Paratek Pharmaceuticals","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2908-2612","authenticated-orcid":true,"given":"Kelly","family":"Wright","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019g7bh20","id-type":"ROR","asserted-by":"publisher"}],"name":"Paratek Pharmaceuticals","place":["King of Prussia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-9019","authenticated-orcid":true,"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qv6pw23","id-type":"ROR","asserted-by":"publisher"}],"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qv6pw23","id-type":"ROR","asserted-by":"publisher"}],"name":"Element Iowa City (JMI Laboratories)","place":["North Liberty, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"World Health Organization. 2024. The top 10 causes of death. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae316"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCC.0000000000000550"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"e_1_3_2_7_2","first-page":"4","article-title":"Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT)","volume":"76","author":"Wiersinga WJ","year":"2018","unstructured":"Wiersinga WJ, Bonten MJ, Boersma WG, Jonkers RE, Aleva RM, Kullberg BJ, Schouten JA, Degener JE, van de Garde EMW, Verheij TJ, Sachs APE, Prins JM. 2018. Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT). Neth J Med 76:4\u201313.","journal-title":"Neth J Med"},{"key":"e_1_3_2_8_2","unstructured":"Excellence NIfHaC. 2019. Pneumonia (community-acquired): antimicrobial prescribing. Available from: https:\/\/www.nice.org.uk\/guidance\/ng138\/chapter\/Recommendations"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir531"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-2331"},{"key":"e_1_3_2_11_2","volume-title":"M100Ed34Performance standards for antimicrobial susceptibility testing: 34th Informational Supplement","author":"CLSI","year":"2024","unstructured":"CLSI. 2024. M100Ed34. Performance standards for antimicrobial susceptibility testing: 34th Informational Supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.07.035"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae470"},{"key":"e_1_3_2_14_2","volume-title":"M52 Ed1Verification of commercial microbial identification and antimicrobial susceptibility testing systems","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. M52 Ed1. Verification of commercial microbial identification and antimicrobial susceptibility testing systems. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01934-17"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06341-y"},{"key":"e_1_3_2_17_2","unstructured":"CEFTRIAXONE - CEFTRIAXONE sodium injection powder for solution 2017. 2024. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=4387. Retrieved 22 Nov 2024."},{"key":"e_1_3_2_18_2","unstructured":"VANTIN - Cefpodoxime proxetil granule for suspension; 2023. 2024. Available from: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=1034. Retrieved 22 Nov 2024."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa084"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1995.00430120050006"},{"key":"e_1_3_2_21_2","first-page":"267","article-title":"Community acquired pneumonia: from intravenous to oral cephalosporin sequential therapy","volume":"128","author":"Fern\u00e1ndez P","year":"2000","unstructured":"Fern\u00e1ndez P, San Mart\u00edn L. 2000. Community acquired pneumonia: from intravenous to oral cephalosporin sequential therapy. Rev Med Chil 128:267\u2013272.","journal-title":"Rev Med Chil"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2075"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00027-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/jcm.00027-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T13:00:42Z","timestamp":1755090042000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/jcm.00027-25"}},"subtitle":[],"editor":[{"given":"Jennifer","family":"Dien Bard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,13]]}},"alternative-id":["10.1128\/jcm.00027-25"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00027-25","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"assertion":[{"value":"2025-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00027-25"}}